09/06/2015

ESTEVE RECEIVES ASPID AWARD FOR TRIPTOMAX

The Triptomax communication campaign has been awarded a silver ASPID in the category of Integrated Advertising. These Ibero-American Health and Pharmacy awards are granted every year to the best advertising works in Spain.

ESTEVE's Triptomax is a dietary supplement that helps naturally restore a positive mood. Its advertising campaign, consisting of TV commercials, external and in-store ads, and merchandising, has been awarded a silver ASPID in the 19th edition of these awards, held at the World Trade Center of Barcelona.

The Triptomax campaign targets people aged 35 to 55 years who are active but feel overwhelmed by different circumstances. Unlike the advertising of other multivitamin products, which address the problem or the need, this campaign focuses on the benefit provided by this product: seeing and living life in a positive way.

The Ibero-American Health and Pharmacy ASPID Awards are convened every year by the magazine PMFarma in collaboration with the Sepromark Marketing Club, and acknowledge the creativity in advertising pharmaceutical products and the communication of services related to health and healthcare.


You can follow ESTEVE on Twitter at this link: twitter.com/esteve_news.

Last news

  • ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY

    Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spain

    read more
  • NURSES OFFER CARE AND PREVENTION OF DRY EYE, A CONDITION THAT AFFECTS 60% OF PEOPLE OLDER THAN 45 YEARS

    Dry eye care and prevention is a pending issue in the Spanish society and a source of great concern for specific patients, such as those admitted to Intensive Care Units.

    The longer time...

    read more
  • ONE THIRD OF DIABETIC PATIENTS ARE OLDER THAN 75 YEARS AND THEIR HYPOGLYCEMIA GOES UNDETECTED IN 1 OUT OF 5 CASES

    According to experts attending Diabeclass, a meeting organized by ESTEVE
    at its corporate headquarters titled "Managing elderly patients with
    type 2 diabetes".

    The priority ...

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.